Compare Adaptive Biotechnologies Corp (ADPT) vs ARMOUR Residential REIT, Inc. (ARR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ARMOUR Residential REIT, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while ARMOUR Residential REIT, Inc. trades at $16.92 (market cap $2.11B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and ARMOUR Residential REIT, Inc. pays a 16.96% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ARR | |
|---|---|---|
Market Cap | $3.33B | $2.11B |
Sector | Health | Financials |
52-Week High | $22.37 | $19.12 |
52-Week Low | $10.24 | $14.05 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 16.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ARR trades at $16.98, down 0.88% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows a low P/E of 6.9 and P/B of 0.91, with strong net income margin of 95.99% in 2025. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 missed. Dividend payments of $0.24 per share continue consistently, supporting income appeal amid mixed analyst sentiment.
Outlook is cautious with 60% hold ratings; consensus target is $18.50 offering ~9% upside. Risks include volatile cash flows from large investing activities and reliance on dividend sustainability. Institutional sentiment is divided, with Zacks rating it Strong Sell on June 23, 2026, contrasting with some bullish dividend coverage analyses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →
